MICRO-CT IMAGING OF AVASTIN-TREATED MICE WITH LS174TT TUMORS

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 目的：研究安维汀治疗后血管正常化的假说。我们将使用Isovue 370的动态微CT来可视化灌注，使用脂质体造影剂的静态微CT来可视化肿瘤中的渗透性。将于2010年1月5日将12只具有存活肿瘤的动物从皮埃蒙特研究中心转移至杜克。6只小鼠将用安维汀处理，6只小鼠将作为对照。治疗包括每两周一次IP给予5 mg/kg安维汀，并将在：1月7日星期四开始的星期四和星期一进行。 第一个成像日将是1月8日星期五。 4个治疗组： 1)对照脂质体，3只动物（CL） 2)对照灌注，3只动物（CP） 3)给药脂质体，3只动物（TL） 4)处理灌注，3只动物（TP） CL组和TL组将于周一通过尾静脉注射脂质体造影剂（0.3 ml/25 g小鼠），每周周一（0小时）和周三（48小时）进行静态显微CT成像。 CP组和TP组将在周五使用动态显微CT每周进行一次成像，以比较灌注。对于这些研究，我们将使用尾静脉导管以0.5ml/25 g小鼠的剂量递送Isovue 370。动物将在每次成像后恢复。我们预计未处理的小鼠（CL，CP）将达到终点，此时它们将需要在1月5日开始的第0天的约17天内被处死。给药动物（TL、TP）将在约36天内达到终点。因此，将仅对组（CP、CP）中的6只动物进行2周成像。对于未治疗的动物，成像可持续长达5周。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Aim: Study the hypothesis of vascular normalization as a result of Avastin treatment. We will use both dynamic micro-CT with a Isovue 370 to visualize perfusion and static micro-CT with a liposomal contrast agent to visualize permeability in tumors. 12 animals with viable tumors will be transfered from Piedmont Research Center to Duke on 1-5-10. 6 mice will be treated with Avastin and 6 mice will be controls. Treatment involves 5mg/kg of Avastin given IP biweekly, and will take place on: Thursdays and Mondays starting on Thursday January 7th. The first imaging day will be Friday January 8th. 4 treatment groups: 1) Control Liposome, 3 animals (CL) 2) Control Perfusion, 3 animals (CP) 3) Treated Liposome, 3 animals ( TL) 4) Treated Perfusion, 3 animals (TP) The groups CL and TL will be injected via tail vein with liposomal contrast ( 0.3 ml/25g mouse) on Mondays and static micro-CT imaging will take place on Mondays (0 hours) and Wednesdays (48hours) every week. The groups CP and TP will be imaged once per week on Fridays using dynamic micro-CT to compare perfusion. For these stusdies we will use a tail vein catheter to deliver Isovue 370 in a dose of 0.5ml/25 g mouse). Animals will be recovered after each imaging session. We expect that untreated mice (CL, CP) will reach the end point when they will need to be sacrificed in about 17 days with Day 0 starting on January 5th. The treated animals (TL, TP) will reach the endpoint in about 36 days. Therefore, imaging the 6 animals in groups (CP,CP) will take place for only 2 weeks. For untreated animals the imaging could last up to 5 weeks.